Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: Reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2240-2249

  O'Donnell, Peter H ^a   Artz, Andrew S ^a   Undevia, Samir D ^a   Pai, Rish K ^b   Del Cerro, Paula ^a   Horowitz, Sarah ^a   Godley, Lucy A ^a   Hart, John ^a   Innocenti, Federico ^a   Larson, Richard A ^a   Odenike, Olatoyosi M ^a   Stock, Wendy ^a   Van Besien, Koen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical results; pharmacotherapeutics; transplant toxicity

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CLONAZEPAM; FLUDARABINE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; ASCITES; BLOOD TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEPATOSPLENOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LATE SINUSOIDAL OBSTRUCTION SYNDROME; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; VEIN OCCLUSION; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG COMBINATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 78650051826     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.520773     Document Type: Article

References (38)

1. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728-5738.
2. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-838.
3. Galton DA. Myleran in chronic myeloid leukaemia; results of treatment. Lancet 1953;264:208-213.
4. Canellos GP, Griffin JD. Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. Semin Oncol 1985;12:281-288.
5. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graftversus- host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8:477-485.
6. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-3060.
7. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003;17:63-70.
8. Dix SP, Wingard JR, Mullins RE, et al. Associationof busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17:225-230.
9. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61.
10. Essell JH, Thompson JM, Harman GS, et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/ cyclophosphamide. Blood 1992;79:2784-2788.
11. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101: 2043-2048.
12. Dulley FL, Kanfer EJ, Appelbaum FR, et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987;43:870-873.
13. Moscardo F, Urbano-Ispizua A, Sanz GF, et al. Positive selection for CD34 reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003;31:545-550.
14. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
15. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002;8:468-476.
16. Grochow LB. Parenteral busulfan: is therapeutic monitoring still warranted? Biol Blood Marrow Transplant 2002;8:465-467.
17. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998;20:543-549.
18. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008;28:1502-1510.
19. Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006;37:307-310.
20. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002;8:619-624.
21. Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 2003;7(Suppl. 3):12-18.
22. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 1994;4:147-164.
23. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-1161.
24. Vassal G, Re M, Gouyette A. Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr A 1988;428:357-361.
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
26. Dewe W. Review of statistical methodologies used to compare (bio)assays. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:2208-2213.
27. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104:857-864.
28. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353.
29. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reducedintensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:472-479.
30. Beri R, Chunduri S, Sweiss K, et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010;45:249-253.
31. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008;14:1936-1949.
32. Lindley C, Shea T, McCune J, et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 2004;15:453-459.
33. Walko CM, McLeod H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol 2009;6:153-162.
34. Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999;24:891-895.
35. van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine- melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009; 15:610-617.
36. Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008;14:220-228.
37. Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versushost disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009;15:101-108.
38. Wood WA, Walko CM, Rao KV, et al. Identification of an AUC of 7603 umol-min/hr per day x 4 days as the maximum tolerated dose (MTD) of IV continuous infusion (CI) busulfan (Bu) with fixed dose fludarabine (Flu) in a pharmacokinetically-based dose phase I study in patients (pts) with hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009;15(Suppl.):Abstract 270.